Kalorama has been researching and examining the development of cancer vaccines
for seven years. In April 2010, the cancer vaccine market experienced one of
the biggest achievements in the therapeutic vaccine treatment of cancer - the
approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to
the success of cervical cancer vaccine products, has created a viable market
for what was merely a speculative area just one decade ago. Even with
achievements for some companies, numerous vaccines with apparently strong
prospects have been hit by developmental delays and failures. These include
CancerVax' s Canvaxin, Aphton' s Insegia, Progenics' GMK vaccine, and Biomira' s
Theratope. Despite setbacks many developers are hopeful of a turnaround. With
a couple prophylactic vaccines for cervical cancer on the market, a few select
therapeutic vaccine approvals and several therapeutic vaccines on a promising
path to commercialization, the market could see a surge of regulatory activity
and an influx of market opportunities.
This Kalorama Information report - Emerging Cancer Vaccines: Forecasts,
Developments and Pipeline Analysis - focuses on both preventive and
therapeutic cancer vaccines in development. The following cancers for which
there are vaccines in development or where there is a potential are profiled:
Cervical
Colon/Rectal
Lung
Lymphoma
Melanoma
Prostate
Breast
Gastrointestinal
Renal
Brain
Bladder
Ovarian
Leukemia
The report includes statistical information for cancers by type worldwide,
with special emphasis on the U.S. market. Specifically, cancers where there is
current vaccines development are profiled. Each market segment provides an
overview, descriptions of products available or in development, market
estimates and forecasts for 2010-2015, and competitive analysis of leading
developers for 2015.
The report also includes current issues and trends affecting the industry.
This area of medicine is a new frontier and many of the issues that face the
cancer vaccine market are novel. However, this is a very promising area of
medicine, which will continue to assist in the fight against cancer.
Issues and trends discussed in The Emerging Cancer Vaccine Market include:
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Safety Concerns
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
Economic Conditions and Vaccine Discovery
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information.
For the purpose of this study Kalorama Information conducted interviews with
key industry officials, consultants, health care providers, and government
personnel. These sources were the primary basis in gathering information
specifically relating to revenue and market share data presented in this
report. Specific interviews with pharmaceutical company representatives
included marketing directors, division managers, and development
representatives.
All market data pertains to the world market at the manufacturers' level. The
years outlined in this study include projected markets for 2010 thru 2015.
Compound annual growth rates (CAGRs) are provided for the 2010-2015 for each
vaccine segment covered. Competitive analysis is provided for the year 2015
for the developing and emerging market. The projected competitive analysis for
2015 was based on products in late stage development, probability of approval
and marketing, and demographic trends.
Several companies have promising research and development activities for
cancer vaccines. Additionally, many companies are in early stage development
with a focused effort on providing favorable results in treating cancer. Many
of these companies are:
Accentia
Antigenics
AVAX
Dendreon
GlaxoSmithKline
Merck & Co.
Northwest Biotherapeutics
Oncothyreon
Vaccinogen
Table of Contents
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Disease Burden
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
Introduction
Cancer Descriptions
Timeline of Cancer Vaccine Developments
History and Growth of the Cancer Treatment Market
Types of Vaccines
Antigen/Adjuvant Vaccines
Whole Cell Tumor Vaccines
Dendritic Cell (DC) Vaccines
Viral Vectors and DNA Vaccines
Idiotype Vaccines
Types of Therapeutic Vaccines
Patient-Specific Vaccines
Prostate Specific Antigen
Sialyl Tn
Heat Shock Proteins
Ganglioside Molecules
Carcinoembryonic Antigen (CEA)
MART-1
Tyrosinase
Adjuvants
Industry Structure
Demographics and Statistics
Growing and Aging Population
Tobacco Use and Obesity Increases Cancer Risk
Tobacco Use
Obesity
Life Expectancy and Cancer
CHAPTER THREE: CERVICAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Gardasil/Silgard
Cervarix
Description of Vaccines in Development
V503
RG3484
PV701
Lovaxin C
VGX-3100
CA-9
Market Summary
Current and Potential Competitors and Analysis, 2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Overview
Description of Vaccines on the Market
OncoVAX
Description of Vaccines in Development
OncoVAX
TroVAX
CEA VRP Vaccine (AVX701)
IMA910
CDX-1307
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
GI-4000
GVAX
Oncophage
CRS-207
Lapuleucel-T
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER FIVE: LUNG CANCER VACCINES
Overview
Description of Vaccines in Development
Lucanix
MAGE-A3 Peptide
Stimuvax
EGF Cancer Vaccine
HyperAcute Lung
GI-4000
Oncophage
TG 4010
LungVAX
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
DCVax-Lung
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SIX: LYMPHOMA VACCINES
Overview
Description of Vaccines in Development
BiovaxID
MyVax
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER SEVEN: MELANOMA VACCINES
Overview
Description of Vaccines on the Market
Description of Vaccines in Development
MVAX
Allovectin-7
MDX-1379 with Combination Treatment MDX-010
Oncophage
MAGE-A3 ASCI
ALVAC Vaccine
HyperAcute Melanoma
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
Overview
Description of Vaccines on the Market
Provenge
Description of Vaccines in Development
DCVax-Prostate
GVAX
PROSTVAC-VF
TroVAX
Onyvax-P
MVA-BN Prostate
HyperAcute Prostate
NeuVax
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2015
CHAPTER NINE: BREAST CANCER VACCINES
Overview
Description of Vaccines in Development
Stimuvax
NeuVax
GVAX
AVX701 Vaccine
MVA-BN HER2
Lapuleucel-T
CDX-1307-02
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
CHAPTER FIFTEEN: LEUKEMIA VACCINES
Overview
Description of Vaccines in Development
GVAX-Leukemia
GRNVAC1
PR1 Peptide Vaccine
Market Summary
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Safety Concerns
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
Economic Conditions Affect Investing in Some Cancer Vaccine Discovery
CHAPTER SEVENTEEN THE CANCER VACCINE MARKET: MARKET FORECASTS
Overview
Total Market Size and Forecast
Prophylactic versus Therapeutic Cancer Vaccine Market Size
Market and Competitor Analysis
CHAPTER EIGHTEEN CANCER VACCINE CORPORATE PROFILES
Introduction
Accentia Biopharmaceuticals, Inc.
Antigenics, Inc.
Avax Technologies, Inc.
Dendreon Corporation
GlaxoSmithKline plc
Merck & Company, Inc.
Northwest Biotherapeutics, Inc.
Oncothyreon, Inc
Vaccinogen, Inc.
APPENDIX: COMPANY NAMES AND ADDRESSES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets,
2007-2015
Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2007-2015
Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets
by Percent and Vaccine Indication, 2015
CHAPTER TWO: INTRODUCTION
Table 2- Significant Cancer Vaccine Approvals, 2000-201
Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and
2020, all races, both sexe
Figure 2-1 Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2010 and 2020
Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates
Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates
Table 2-4 World Population by Selected Geographical Region, 2010 - 2050
Figure 2-3 World Population by Selected Geographical Region, 2010-2050
Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-4 Estimated World Population by Age, 2010 and 2050
Table 2-6 Percent of Smokers by Country
Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions
Table 2-7 Estimated Obesity by Country 2009 Estimates
Figure 2-6 Estimated Obesity by Country as a Portion of Total Population
2009 Estimates
Figure 2-7 Increases in Obesity by Country - 2007 and 2009 Figures
Table 2-8 Life Expectancy at Birth by Selected Countries, 2006
Figure 2-8 United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2006
Figure 2-9 United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2006
Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of
Death, All Races, Both Sexes, 2006
CERVICAL CANCER VACCINES
Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
Table 3-2 Cervical Cancer Vaccines Approved and in the Pipeline
Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015
Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015
Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading
Suppliers Shares by Market Revenues, Projected 2015
Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015
COLON/RECTAL CANCER VACCINES
Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country,
2010
Table 4-2 Colon/Rectal Cancer Vaccines in the Pipeline
LUNG CANCER VACCINES
Table 5-1 TYPES OF PRIMARY LUNG CANCER
Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010
Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010
Table 5-3 Lung Cancer Vaccines in the Pipeline
LYMPHOMA VACCINES
Table 6-1 CLASSIFICATION OF NON-HODGKIN' S LYMPHOMAS
Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010
Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010
Table 6-3 Lymphoma Vaccines in the Pipeline
MELANOMA VACCINES
Table 7-1 MALIGNANT CONDITIONS OF THE SKIN
Table 7-2 Estimated World Incidence of Melanoma by Country, 2010
Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010
Table 7-3 Melanoma Vaccines in the Pipeline
Table 7-3 (continued) Melanoma Vaccines in the Pipeline
Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015
Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015
Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares
by Market Revenues, Projected 2015
Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines,
2007-2015
PROSTATE CANCER VACCINES
Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
Table 8-2 Prostate Cancer Vaccines in the Pipeline
Table 8-2 (continued) Prostate Cancer Vaccines in the Pipeline
Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015
Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015
Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate
Vaccines, 2010-2015
BREAST CANCER VACCINES
Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
Table 9-2 Breast Cancer Vaccines in the Pipeline
GASTROINTESTINAL CANCER VACCINES
Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by
Country, 2010
Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by
Country, 2010
Table 10-2 Gastrointestinal Cancer Vaccines in the Pipeline
RENAL CANCER VACCINES
Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
Table 11-2 Renal Cancer Vaccines in the Pipeline
BRAIN CANCER VACCINES
Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
Table 12-2 Brain Cancer Vaccines in the Pipeline
BLADDER CANCER VACCINES
Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
Table 13-2 Bladder Cancer Vaccines in the Pipeline
OVARIAN CANCER VACCINES
Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
Table 14-2 Ovarian Cancer Vaccines in the Pipeline
LEUKEMIA VACCINES
Table 15-1 TYPES OF LEUKEMIA
Table 15-2 Estimated World Incidence of Leukemia by Country, 2010
Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010
Table 15-3 Leukemia Vaccines in the Pipeline
ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Table 16-1 Cancer Detection Tests
Table 16-2 Early Safety Statistics Concerning HPV Vaccination
THE CANCER VACCINE MARKET: MARKET FORECASTS
Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2007-2015
Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2007-2015
Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets by Percent and Vaccine Indication, 2015
Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine
Markets, 2007-2015 208
Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine
Markets by Percent, 2015
CANCER VACCINE CORPORATE PROFILE: COMPANY NAMES AND ADDRESSES
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition published by Kalorama Information in September 1, 2010. This report consists of 216 Pages and the price starts from US $ 3995.
The contents of this page may be different from the latest version. Please contact us for details.
